Ligand validation:4PL5

PEU: 2,5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50,53,56,59,62,65,68,71,74,77,80-HEPTACOSAOXADOOCTACONTAN-82-OL

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
4PL5_PEU_A_1004	7%	72%	0.259	0.817	0.46	0.6	-	-	0	0	37%	0.3735
4PL4_PEU_A_1003	16%	40%	0.179	0.883	0.64	1.68	-	2	0	0	23%	0.2289
7CG8_PEU_B_201	60%	73%	0.083	0.948	0.57	0.49	-	-	0	0	55%	0.5542
2ERB_PEU_B_1001	34%	71%	0.153	0.833	0.54	0.56	-	-	10	0	100%	1
4ORX_PEU_B_201	33%	82%	0.14	0.834	0.47	0.33	-	-	8	0	92%	0.9157
4ORY_PEU_E_201	33%	83%	0.175	0.868	0.5	0.29	-	-	4	0	92%	0.9157
3Q00_PEU_A_305	31%	73%	0.125	0.949	0.55	0.51	-	-	0	0	12%	12.049999999999999

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.